FDA approvals
2014 GLP-1 FDA approvals & regulatory actions
3 regulatory events affecting GLP-1 medications in 2014.
- Original approval
Saxenda
Liraglutide approved at 3 mg dose for chronic weight management in adults with BMI ≥30 (or ≥27 with comorbidity). First daily GLP-1 for obesity indication.
Read on fda.gov → - Original approval
Trulicity
Once-weekly dulaglutide approved for type 2 diabetes. Single-use autoinjector pen with pre-attached needle.
Read on fda.gov → - Original approval
Tanzeum
Once-weekly albiglutide approved for type 2 diabetes.
Read on fda.gov →